Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Genitourinary 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 74Kidney Neoplasms 27Prostatic Neoplasms 16Neoplasm Metastasis 11Urinary Bladder Neoplasms 5Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Neuroendocrine Tumors 3Carcinoma, Transitional Cell 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Margins of Excision 2Insulinoma 2Glucagonoma 2Gastrinoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Islet Cell 2Urothelial Cancer 1Ureteral Neoplasms 1Tuberous Sclerosis 1Thrombocytosis 1Testicular Neoplasms 1Renal Cell Cancer Metastatic 1Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1Primary Myelofibrosis 1

Interventions

Gelclair 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mucositis × Everolimus × Genitourinary × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡